In conclusion, although preclinical research shows promise for NLRP3 inhibitors to reduce cardiac IRI in settings of diseased hearts (diabetic, aged, and metabolic syndrome), and novel NLRP3 inflammasome inhibitors are being developed, the first cardioprotective trial with these selective NLRP3 inhibitors is still eagerly awaited [91]. This evidence concerns the gene NLRP3 and metabolic syndrome.